Phil Ambery/LinkedIn
Jun 21, 2026, 08:04
Phil Ambery: Next-Generation Endothelin Therapeutics Renew Interest in a Proven Pathway
Phil Ambery, Scientific Advisory Board Member at PTEN Research, shared a post on LinkedIn about a recent article by Anthony P. Davenport, published in Canadian Journal of Physiology and Pharmacology, adding:
“As we get to the last lap of the ZENITH High proteinuria study, a review article with our colleagues and collaborators at University of Cambridge detailing the great promise in targeting endothelin biology.”
Title: Next-generation therapeutics and renaissance of legacy drugs targeting the endothelin system
Authors: Anthony P. Davenport, Majid Anwar, Rhoda E. Kuc, Lena Brynne, Anne-Kristina Mercier, Magnus Åstrand, Peter J Greasley, Philip Ambery, Janet J. Maguire
Stay updated on all scientific advances Hemostasis Today.
Anne-Kristina Mercier
Anthony P. Davenport
Canadian Journal of Physiology and Pharmacology
Endothelin
Health
Hematology
Hemostasis
Hemostasis News
Hemostasis Today
Janet J. Maguire
Lena Brynne
Magnus Åstrand
Majid Anwar
Medicine
Peter J Greasley
Phil Ambery
Philip Ambery
Rhoda E. Kuc
ZENITH High proteinuria study
-
Sep 29, 2026, 19:00Caitlin Raymond: Can Artificial Blood Solve Blood Supply Shortages?
-
Sep 29, 2026, 18:51Chaza Alaji: Dyslipidemia, Thrombosis and the DIC Diagnostic Trap
-
Sep 29, 2026, 17:31Rajnikant Patel: Bridging Ayurvedic Concepts and Modern Toxin-Mediated Disease
-
Sep 29, 2026, 17:13Nicholas Lang։ A Meaningful Case of Immune Thrombocytopenia
-
Sep 29, 2026, 16:55Ayatullah Gamal Wahab: When the CBC Lies
-
Sep 29, 2026, 16:35Jonathan Douxfils: Navigating the VTE Risk Continuum in Reproductive Medicine
-
Sep 29, 2026, 16:35Chaima Rajeh: Types of Anemia and Their Laboratory Features
-
Sep 29, 2026, 16:27Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge